Skip to main content

Bone diseases

Osteoporosis

01-11-2022 | Osteoporosis | News

Abaloparatide recommended for EU approval to treat osteoporosis

Click through for more details

04-10-2022 | Systemic sclerosis | News

Elevated risk for osteoporotic fractures in women with SSc

Findings from two studies suggest that more attention may need to be given to the prevention of osteoporotic fractures among women with systemic sclerosis.

21-06-2022 | Glucocorticoids | News

Low-dose glucocorticoids show no negative impact on BMD

Low glucocorticoid doses are not associated with reduced bone mineral density in people with inflammatory rheumatic and musculoskeletal diseases, observational study findings indicate.

26-05-2022 | Osteoporosis | News

UK recommendations support regular exercise for people with osteoporosis

People with osteoporosis should do regular exercise to maximize bone health and reduce fall risk, says an expert consensus statement published in the British Journal of Sports Medicine.

18-02-2022 | Osteoporosis | News

EMA recommends approval of teriparatide biosimilar for osteoporosis

Click through for further details on this announcement

Rituximab and rheumatology practice in the COVID-19 era

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

11-01-2022 | Osteoporosis | News

Hip fracture risk higher during risedronate versus alendronate drug holiday

The risk for hip fracture is higher during a treatment break from risedronate than it is during a break from alendronate, study findings indicate.

24-11-2021 | Osteoporosis | News

Bisphosphonates ‘likely to be beneficial’ for most older women with osteoporosis

Findings from a meta-analysis suggest that bisphosphonate therapy for osteoporosis is most likely to benefit postmenopausal women who have a life expectancy of more than 12 months.

05-10-2021 | Rheumatoid arthritis | News

Denosumab benefits short-lived following discontinuation

Discontinuing denosumab after 1 year of treatment quickly leads to reversal of its inhibitory effect on bone turnover markers and improvements in bone mineral density among people using glucocorticoids for rheumatoid arthritis, research shows.

Anifrolumab for the treatment of lupus

Anifrolumab for the treatment of SLE

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

New additions to the Adis Journal Club

Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

03-08-2021 | Rheumatoid arthritis | News

RA vertebral fracture risk increased with low-dose glucocorticoids

In patients with rheumatoid arthritis, low-dose glucocorticoids are associated with an increased risk for vertebral fracture, but not with overall or non-vertebral fractures, show findings from a UK-based retrospective cohort study.

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

ACR Convergence 2021 highlights

ACR Convergence 2021

3–9 November: Keep up with the latest news and interviews from the conference.

Febuxostat and cardiovascular risk in people with gout

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

Osteoporosis illustration

28-04-2021 | BSR 2021 | Conference coverage | News

Suboptimal prescribing of osteoporosis medications in people with polymyalgia rheumatica

Less than half of patients with polymyalgia rheumatica are prescribed medications for osteoporosis, despite clinical guidelines recommending bone protection for those on long-term glucocorticoid treatment, research suggests.

05-01-2021 | Rheumatoid arthritis | News

Parallel glucocorticoid, PPI use linked to increased fracture risk in RA

Concomitant use of oral glucocorticoids and proton pump inhibitors significantly increases the risk for osteoporotic fractures in people with rheumatoid arthritis, with the combined effect greater than that for each drug class alone, research suggests.

Telemedicine in rheumatology

Telemedicine in rheumatology: COVID-19 and beyond

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

29-10-2020 | Rheumatoid arthritis | News

Excess multimorbidity begins early in RA disease course

Multimorbidity is more common in people with versus without rheumatoid arthritis, occurs early in the disease course, and progresses more rapidly, US study data show.